Sagimet Biosciences, Inc. (SGMT)
10.80
-0.29
(-2.61%)
USD |
NASDAQ |
Sep 21, 16:00
10.80
0.00 (0.00%)
After-Hours: 20:00
Sagimet Biosciences Total Liabilities (Quarterly) : 7.275M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 7.275M |
| March 31, 2026 | 5.297M |
| December 31, 2025 | 5.101M |
| September 30, 2025 | 9.146M |
| June 30, 2025 | 7.247M |
| March 31, 2025 | 7.18M |
| December 31, 2024 | 4.454M |
| September 30, 2024 | 4.092M |
| June 30, 2024 | 5.728M |
| March 31, 2024 | 4.51M |
| December 31, 2023 | 5.654M |
| Date | Value |
|---|---|
| September 30, 2023 | 5.05M |
| June 30, 2023 | 5.292M |
| March 31, 2023 | 5.332M |
| December 31, 2022 | |
| September 30, 2022 | |
| June 30, 2022 | |
| March 31, 2022 | |
| December 31, 2021 | |
| September 30, 2021 | |
| June 30, 2021 | |
| March 31, 2021 | 3.161M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 436.29M |
| Alnylam Pharmaceuticals, Inc. | 4.205B |
| Anika Therapeutics, Inc. | 46.19M |
| Savara, Inc. | 48.48M |
| Vericel Corp. | 132.82M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 263.43M |
| Shareholders Equity (Quarterly) | 256.16M |
| Debt to Equity Ratio | 0.0076 |
| Current Ratio | 44.94 |
| Net Debt Paydown Yield | -0.08% |